Newsroom | 100786 results

ROCHESTER, Minn.--(BUSINESS WIRE)--G-Link is a first-in-class modular adaptor protein technology designed to enable and enhance T-cell-targeting delivery across CAR T workflows....

SCHLIEREN, Switzerland & SAN DIEGO--(BUSINESS WIRE)--InSphero AG, a global leader in advanced 3D in vitro models and services for drug safety and efficacy testing, today announced the acquisition of PhenoVista Biosciences, Inc., a premier provider of high-content imaging and phenotypic assay technologies based in San Diego, California. The acquisition marks an important new chapter for PhenoVista Biosciences, enabling the company to significantly expand its scientific and commercial impact by c...

PARIS--(BUSINESS WIRE)--Regulatory News : GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour le traitement des maladies neurodégénératives de la rétine et du système nerveux central, annonce que l’ensemble des 28 résolutions soumises au vote de l’Assemblée Générale Mixte des actionnaires, tenue le 19 mai 2026 et présidée par Laurence Rodriguez, Directrice...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that all 28 resolutions submitted for shareholders’ vote at the Combined Shareholders’ Meeting held on May 19, 2026, and chaired by Laurence Rodriguez, Chief Executive Officer of the Company, were approved....

MADISON, Wis.--(BUSINESS WIRE)--FUJIFILM Cellular Dynamics, Inc., a pioneering global developer and manufacturer of human-induced pluripotent stem cells (iPSCs), today celebrated the opening of its new headquarters and iPSC development and manufacturing facility in its Madison home. The new site is expected to quadruple the capacity for the company’s iPSC-based research products and services manufacturing footprint and expand capabilities across FUJIFILM Cellular Dynamics’ research product port...

MENLO PARK, Calif.--(BUSINESS WIRE)--Jupiter Endovascular announced positive results from its SPIRARE II pivotal trial at EuroPCR showing the trial met both of its primary endpoints....

SAN CARLOS, Calif.--(BUSINESS WIRE)--Engage Biologics Inc. (“Engage”), a preclinical biotechnology company pioneering non-viral DNA delivery, today announced that it has been acquired by Eli Lilly and Company (“Lilly”). Engage is developing the Tethosome platform, a novel non-viral DNA delivery system designed to overcome key limitations in DNA delivery, including potency, tolerability, and redosability. The platform combines engineered DNA payloads with lipid nanoparticle delivery and an mRNA-...

PITTSBURGH--(BUSINESS WIRE)--CytoAgents expanded its Scientific Advisory Board with the appointments of Dr. Michael Wechsler and Dr. Johann Gudjonsson to support pipeline growth....

MADISON, Wis.--(BUSINESS WIRE)--Invenra, Inc., a biotechnology company pioneering multispecific antibody therapeutics, today announced the appointment of Nancy J. Sandy as Chief Commercial Officer. The hire marks a significant step in the Invenra strategy to bring its expanding platform portfolio, including its B-Body® bispecific and newly launched T-Body™ trispecific antibody platforms, to pharmaceutical and biotech partners worldwide. Invenra enters this next chapter with strong momentum. The...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Predicta Biosciences, a company building ultra-sensitive molecular and immune diagnostic platforms, today announced the appointment of Craig L. Tendler, M.D., as an independent director to its Board of Directors. Dr. Tendler brings decades of experience designing and executing oncology and hematology development programs including the integration of biomarkers and diagnostics, from early development and proof of concept through registration. Over the course of...